2021
DOI: 10.5281/zenodo.4596571
|View full text |Cite
|
Sign up to set email alerts
|

Accompanying data - "The quandary of DNA-based treatment assessment in de novo metastatic prostate cancer in the era of precision oncology"

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles